ChiCTR2100048690 版本V1.4 版本创建时间2022/02/20 22:45:58 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048690 

最近更新日期:

Date of Last Refreshed on:

2022-02-20 22:22:01 

注册时间:

Date of Registration:

2021-07-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

情志刺激甲状腺结节病变的个性化差异与其个性化有效防治

Public title:

Personalized difference and individualized effective prevention and treatment of emotion-stimulated thyroid nodule lesions

注册题目简写:

English Acronym:

研究课题的正式科学名称:

情志刺激甲状腺结节病变的个性化差异与其个性化有效防治

Scientific title:

Personalized difference and individualized effective prevention and treatment of emotion-stimulated thyroid nodule lesions

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨萍 

研究负责人:

王少莲 

Applicant:

Yang Ping 

Study leader:

Wang Shaolian 

申请注册联系人电话:

Applicant telephone:

+86 13553166355

研究负责人电话:

Study leader's
telephone:

+86 15318816221

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yp1123yangping@126.com

研究负责人电子邮件:

Study leader's E-mail:

wsl197107@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

山东中医药大学

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市历下区经十路16369号

研究负责人通讯地址:

山东省济南市历下区解放路105号

Applicant address:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

Study leader's address:

105 Jiefang Road, Lixia District, Ji'nan, Shandong

申请注册联系人邮政编码:

Applicant postcode:

250000

研究负责人邮政编码:

Study leader's postcode:

250000

申请人所在单位:

山东中医药大学

Applicant's institution:

Shandong Traditional Chinese Medicine University

研究负责人所在单位:

山东第一医科大学附属济南市中心医院

Affiliation of the Leader:

Jinan Central Hospital Affiliated to Shandong First Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

AF/SC-08/04.0

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

济南市中心医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jinan Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-06-15 00:00:00

伦理委员会联系人:

温清

Contact Name of the ethic committee:

Wen Qing

伦理委员会联系地址:

山东省济南市历下区解放路105号

Contact Address of the ethic committee:

105 Jiefang Road, Lixia District, Ji'nan, Shandong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东中医药大学

Primary sponsor:

Shandong Traditional Chinese Medicine University

研究实施负责(组长)单位地址:

山东省济南市历下区经十路16369号

Primary sponsor's address:

16369 Jingshi Road, Lixia District, Ji'nan, Shandong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东中医药大学

具体地址:

历下区经十路16369号

Institution
hospital:

Shandong Traditional Chinese Medicine University

Address:

16369 Jingshi Road, Lixia District

经费或物资来源:

济南市科技局

Source(s) of funding:

Ji'nan Science and Technology Bureau

研究疾病:

甲状腺结节  

Target disease:

Thyroid Nodule

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1.情志刺激致病与个性倾向气质类型的差异相关性研究; 2.甲状腺结节患者不同个性特征和气质类型病情变化的差异相关性研究; 3.观察并评价“甲节减”外用新制剂治疗甲状腺结节两型患者的临床疗效。  

Objectives of Study:

1.Study on the difference correlation between emotional stimulation and pathogenic personality tendency and temperament type; 2.Study on the difference correlation of different personality characteristics and temperament types in patients with thyroid nodule; 3. Observe and evaluate the clinical efficacy of the new topical preparation "A Decrease" in the treatment of two types of thyroid nodules.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.性别不限,年龄18-65周岁;
2.甲状腺超声提示结节,TI-RADS标准分类为3类或4a/4b类;
3.甲状腺功能(TSH、FT3、FT4)及甲状腺抗体三项(TRAb、TPOAb、TGAb)正常;
4.根据病史、症状、体征及相关化验检查进行评估,排除恶性结节;
5.心理量表测评结果为内倾型抑郁质和外倾性胆汁质;
6.理解并配合本临床研究,并可独立签署知情同意书。

Inclusion criteria

1.No gender limitation, 18-65 years old;
2.Thyroid nodules were indicated by ultrasound, and the standard classification of TI-RADS was Class 3 or Class 4A / 4B;
3.Normal thyroid function (TSH, FT3, FT4) and thyroid antibody (TRAB, TPOAb, TGAB);
4.Assess according to the history, symptoms, signs and relevant laboratory tests to exclude malignant nodules;
5.The results of psychological scale were introverted depressive temperament and extroverted choleric temperament;
6. Understand and cooperate with the clinical study, and can independently sign the informed consent.

排除标准:

1.正在服用治疗甲状腺疾病药物者;
2.精神障碍疾病者;
3.孕妇或哺乳期妇女;
4.正参加其它临床试验者;
5.易过敏体质或有心脑肾等系统重大疾病者。

Exclusion criteria:

1. People taking medication for thyroid disease;
2. People with mental disorders;
3. Pregnant or lactating women;
4. Participating in other clinical trials;
5. People who are prone to allergies or have heart, brain, kidney and other major diseases.

研究实施时间:

Study execute time:

From 2021-07-15 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-15 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

内倾型抑郁质观察组

样本量:

45

Group:

Observation group of introverted melancholia

Sample size:

干预措施:

“甲节减”

干预措施代码:

Intervention:

"Armour reduction"

Intervention code:

组别:

内倾型抑郁质对照组

样本量:

45

Group:

Introverted depressive disorder control group

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

Placebo

Intervention code:

组别:

外倾型胆汁质观察组

样本量:

45

Group:

Extroversion bile quality observation group

Sample size:

干预措施:

“甲节减”

干预措施代码:

Intervention:

"Armour reduction"

Intervention code:

组别:

外倾型胆汁质对照组

样本量:

45

Group:

Extroversion choleric control group

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

Placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东第一医科大学附属济南市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Ji'nan Central Hospital Affiliated to Shandong First Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

甲状腺超声

指标类型:

主要指标

Outcome:

Thyroid ultrasound

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甲状腺功能

指标类型:

主要指标

Outcome:

Thyroid function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甲状腺相关抗体

指标类型:

次要指标

Outcome:

Thyroid associated antibody

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝肾功能

指标类型:

副作用指标

Outcome:

Hepatic and renal function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮肤过敏反应

指标类型:

副作用指标

Outcome:

Skin sensitivity effect

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状评价

指标类型:

次要指标

Outcome:

Symptom assessment

Type:

Secondary indicator

测量时间点:

测量方法:

《临床疗效观察表》

Measure time point of outcome:

Measure method:

Clinical Efficacy Observation Table

指标中文名:

安全性评价

指标类型:

次要指标

Outcome:

Safety evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

山东第一医科大学附属济南市中心医院医生,计算机产生的随机数字进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Doctor of Jinan Central Hospital Affiliated to Shandong First Medical University,Computer generated random numbers for random grouping。

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年6月1日-2023年12月31日,期刊文献

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

June 1, 2022 - December 31, 2023, Journal of Literature

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel表格进行数据录入存档,word文档保存原始数据照片,spss软件进行数据统计分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel forms are used for data entry and archiving, Word documents are used for original data photos, and SPSS software is used for data statistical analysis.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-12 11:54:16